Loading provider…
Loading provider…
Internal Medicine Physician in Nashville, TN
NPI: 1003801788Primary Practice Location
TRISTAR CENTENNIAL MEDICAL CENTER
2220 Patterson St, Nashville, TN
Primary Employer
DBA the Frist Clinic
tristarmedgroup.com
HQ Phone
Get MD John's Phone Numberphone_androidMobile
Get MD John's MobileLooking to connect with more Physicians?
Dmand AI gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Get Started for Freearrow_outwardTN State Medical License
TN State Medical License
1988 - 2026

American Board of Internal Medicine
Internal Medicine
Vanderbilt University Medical Center
vumc.org
Residency • Internal Medicine
1986 - 1989
Vanderbilt University School Of Medicine
medschool.vanderbilt.edu
Medical School
Until 1986
| # | Procedure Code (CPT®/HCPCS II) | Procedure Patients | Procedure Volume |
|---|---|---|---|
| 1 | 99213Established patient office or other outpatient visit, typically 15 minutes | 152 | 239 |
| 2 | G0439Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | 147 | 147 |
| 3 | 99214Established patient office or other outpatient visit, 30-39 minutes | 112 | 207 |
| 4 | G0009Administration of pneumococcal vaccine | 15 | 15 |
| 5 | 90677Pneumococcal conjugate vaccine, 20 valent (pcv20), for intramuscular use | 13 | 13 |
Empagliflozin: Role in Treatment Options for Patients with Type 2 Diabetes Mellitus
Authors: Anderson, John E, Wright, Eugene E, Shaefer, Charles F
Journal: Diabetes Ther
Publication Date: 2016-11-11
A Practice-Based Research Network Focused on Comparative Effectiveness Research in Type 2 Diabetes Management
Authors: Andrew Rhinehart
Publication Date: 2013-05
Injecting New Ideas Into Managing Type 2 Diabetes: Evolving Roles of GLP-1 Receptor Agonists.
Lead Sponsor: Sanofi
Intervention / Treatment: DRUG: Insulin glargine (HOE901), DRUG: Metformin (Background Drug), DRUG: Insulin glargine/lixisenatide (HOE901/AVE0010)
Lead Sponsor: Sanofi
Intervention / Treatment: DRUG: Background Therapy, DRUG: Insulin glargine, 300 U/ml, DRUG: Insulin glargine, 100 U/ml, DRUG: Insulin detemir
Lead Sponsor: Sanofi
Intervention / Treatment: DRUG: Metformin (Background drug), DRUG: Lixisenatide (AVE0010), DRUG: Insulin glulisine QD, DRUG: Insulin glulisine TID, DRUG: Insulin Glargine (Mandatory background drug)